Ankylosing Spondylitis and Axial Spondyloarthritis.
نویسندگان
چکیده
Chronic back pain is common worldwide and is cared for by a variety of providers, but specific, satisfactory treatment is often lacking. Ankylosing spondylitis, an inflammatory disorder that in its extreme form can lead to the bony fusion of vertebral joints, is an uncommon but well-established cause of chronic back pain. During the past decade, ankylosing spondylitis has come to be considered as a subset of the broader and more prevalent diagnostic entity referred to as axial spondyloarthritis. The estimated prevalence of axial spondyloarthritis in the United States is 0.9 to 1.4% of the adult population, similar to that of rheumatoid arthritis.1 Axial spondyloarthritis is generally diagnosed and treated by rheumatologists, and there is specific treatment for it. However, prolonged delay in reaching the diagnosis is common and is usually the result of the failure of recognition by nonrheumatologists.2 This review is intended to enhance awareness and understanding of axial spondyloarthritis and ankylosing spondylitis — and the relationship between the two — in order to facilitate prompt and accurate diagnosis and proper treatment. Recent advances in our understanding and treatment of these conditions are discussed.
منابع مشابه
Might axial myofascial properties and biomechanical mechanisms be relevant to ankylosing spondylitis and axial spondyloarthritis?
Ankylosing spondylitis and axial spondyloarthropathy have characteristic age- and sex-specific onset patterns, typical entheseal lesions, and marked heritability, but the integrative mechanisms causing the pathophysiological and structural alterations remain largely undefined. Myofascial tissues are integrated in the body into webs and networks which permit transmission of passive and active te...
متن کاملThe window of opportunity: a relevant concept for axial spondyloarthritis
The window of opportunity is a concept critical to rheumatoid arthritis treatment. Early treatment changes the outcome of rheumatoid arthritis treatment, in that response rates are higher with earlier disease-modifying anti-rheumatic drug treatment and damage is substantially reduced. Axial spondyloarthritis is an inflammatory axial disease encompassing both nonradiographic axial spondyloarthri...
متن کاملOverview of Drug Therapy for Spondyloarthritis
The axial spondyloarthritides (axial SpA) are a related group of disorders prototypically represented by Ankylosing Spondylitis (AS). Reactive arthritis, psoriatic arthritis, enteropathic arthritis and undifferentiated spondyloarthritis are also included in this family. The prevalence of this group of disorders roughly approximates that of ankylosing spondylitis, affecting 1% of the population ...
متن کاملNew developments in the diagnosis and treatment of axial spondyloarthritis
Spondyloarthritis (SpA) is an umbrella term for a group of diseases sharing genetic, molecular, immunological, clinical and imaging features. The last few years have witnessed a remarkable progress in the understanding of SpA. Notable advances include the recognition of MRI as a sensitive and specific tool for detecting axial inflammation and the recent development and validation of the Assessm...
متن کاملWithdrawal of biologic therapy in axial spondyloarthritis: the experience in early disease.
Tumour necrosis factor-alpha inhibitors (TNF-blockers) are recommended for the treatment of predominantly axial spondyloarthritis (SpA), after failure of non-steroidal anti-inflammatory drugs (NSAIDs). TNF-blockers are very effective drugs and also show a sustained and stable long-term response in axial SpA. A few trials indicated that withdrawal of TNF-blockers in longstanding ankylosing spond...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- The New England journal of medicine
دوره 375 13 شماره
صفحات -
تاریخ انتشار 2016